A calcitonin gene-related peptide antagonist, or a pharmaceutically acceptable salt thereof, said antagonist having the structure of Formula I: X 1 -Y 1 -Z 1 (I) wherein: X 1 is X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17 (SEQ ID NO: 16), wherein X 11 is selected from the group consisting of Ala, Cys, and Gly, and X 12 is selected from the group consisting of Cys, and Ser, provided one of X 11 and X 12 is Cys, X 13 is selected from the group consisting of Arg, Asn, Asp, and Val, X 14 is selected from the group consisting of Leu, Phe, and Thr, X 15 is selected from the group consisting of Ala, Gly, and Ser, X 16 is selected from the group consisting of Ala, Ile, Leu, Ser, and Val, and X 17 is Cys; and Y 1 is selected from the group consisting of -Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn- (SEQ ID NO: 34), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn- (SEQ ID NO: 35), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asp- (SEQ ID NO: 37), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Phe-Pro-Arg-Thr-Asn- (SEQ ID NO: 38), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Asp-Ile-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn- (SEQ ID NO: 39), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Met-Gln-Thr-Tyr-Pro-Arg-Thr-Asp (SEQ ID NO: 40), -Leu-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Thr-Arg-Thr-Asp- (SEQ ID NO: 41), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Asp-Leu-His-Lys-Leu-Gln-Thr-Phe-Pro-Arg-Thr-Asp- (SEQ ID NO: 42), -Met-Leu-Gly-Lys-Leu-Ser-Gln-Asp-Leu-His-Lys-Leu-Gln-Thr-Phe-Pro-Arg-Thr-Asp- (SEQ ID NO: 43), and -Val-Leu-Gly-Lys-Leu-Ser-Gln-Asp-Ile-His-Lys-Leu-Gln-Thr-His-Pro-Arg-Thr-Asp- (SEQ ID NO: 44); and Z 1 is Val-Gly-Ser-Lys-Ala-Phe-NH 2 . X 1 is X 11 -X 12 -X 13 -X 14 -X 15 -X 16 -X 17 (SEQ ID NO: 16), wherein X 11 is selected from the group consisting of Ala, Cys, and Gly, and X 12 is selected from the group consisting of Cys, and Ser, provided one of X 11 and X 12 is Cys, X 13 is selected from the group consisting of Arg, Asn, Asp, and Val, X 14 is selected from the group consisting of Leu, Phe, and Thr, X 15 is selected from the group consisting of Ala, Gly, and Ser, X 16 is selected from the group consisting of Ala, Ile, Leu, Ser, and Val, and X 17 is Cys; and wherein X 11 is selected from the group consisting of Ala, Cys, and Gly, and X 12 is selected from the group consisting of Cys, and Ser, provided one of X 11 and X 12 is Cys, X 13 is selected from the group consisting of Arg, Asn, Asp, and Val, X 14 is selected from the group consisting of Leu, Phe, and Thr, X 15 is selected from the group consisting of Ala, Gly, and Ser, X 16 is selected from the group consisting of Ala, Ile, Leu, Ser, and Val, and X 17 is Cys; and Y 1 is selected from the group consisting of -Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn- (SEQ ID NO: 34), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn- (SEQ ID NO: 35), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asp- (SEQ ID NO: 37), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Phe-Pro-Arg-Thr-Asn- (SEQ ID NO: 38), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Asp-Ile-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn- (SEQ ID NO: 39), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Met-Gln-Thr-Tyr-Pro-Arg-Thr-Asp (SEQ ID NO: 40), -Leu-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Thr-Arg-Thr-Asp- (SEQ ID NO: 41), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Asp-Leu-His-Lys-Leu-Gln-Thr-Phe-Pro-Arg-Thr-Asp- (SEQ ID NO: 42), -Met-Leu-Gly-Lys-Leu-Ser-Gln-Asp-Leu-His-Lys-Leu-Gln-Thr-Phe-Pro-Arg-Thr-Asp- (SEQ ID NO: 43), and -Val-Leu-Gly-Lys-Leu-Ser-Gln-Asp-Ile-His-Lys-Leu-Gln-Thr-His-Pro-Arg-Thr-Asp- (SEQ ID NO: 44); and Z 1 is Val-Gly-Ser-Lys-Ala-Phe-NH 2 . <EOS>